ZBIO

← Markets

ZBIOZenas BioPharma, Inc.

Discussion

Nothing said here yet.

to join the conversation.

—

Tue, Aug 18
3:15 PMYahooZenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Thu, Aug 13
6:00 AMYahooZenas BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Fri, Jul 17
7:13 AMYahooZenas BioPharma Bear Case Overlooks Obexelimab's Commercial Potential, Wedbush Says
Fri, Jul 10
8:58 AMYahooZenas BioPharma (ZBIO): Best IPO Stocks with Huge Upside Potential
Sun, Jun 21
6:31 AMfool.comZenas BioPharma's CEO Purchased 60,000 Company Shares. Here's a Deeper Look at the Transaction.
Thu, Jun 11
3:15 PMYahooZenas BioPharma to Present at the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit
Tue, Jun 2
6:05 PMYahooZenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD), Simultaneously Presented at the EULAR 2026 Congress and Published in the New England Journal of Medicine
Mon, Jun 1
7:06 AMYahooA Look At Zenas BioPharma (ZBIO) Valuation After Strong 1-Year Return And Recent Share Price Weakness
Thu, May 28
6:05 AMYahooZenas BioPharma Announces Submission of Biologics License Application (BLA) to U.S. FDA for Obexelimab in IgG4-RD
Tue, May 19
6:05 AMYahooZenas BioPharma Announces Upcoming Presentation of Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) at EULAR 2026 Congress
Wed, May 13
12:28 PMYahooWhy Zenas BioPharma (ZBIO) Is Down 7.7% After Reporting a Sharply Wider Quarterly Net Loss
5:50 AMYahooZenas BioPharma Announces First Subject Dosed in Phase 1 Clinical Trial of ZB021, a Novel, Potentially Best-in-Class Oral IL-17AA/AF Inhibitor